Vagus Nerve Stimulation for Fibromyalgia: What the Evidence Shows
Introduction: A Case Where the Honest Answer Is "We Don't Know Yet"
Fibromyalgia is a chronic condition characterised by widespread pain, fatigue, disturbed sleep, and cognitive difficulties ("fibro fog"). It is often difficult to treat, and that has understandably driven interest in novel approaches — including vagus nerve stimulation (VNS), which is sometimes marketed to people with fibromyalgia as a drug-free option. The mechanism is plausible. The evidence, however, is genuinely thin, and it would be misleading to suggest otherwise.
This article gives a straight account of where things stand. The short version: there are only two small fibromyalgia-specific trials — an old one using an implanted device and a more recent unblinded one using an ear device — and neither provides convincing proof of benefit. The broader chronic-pain literature is mildly encouraging, but a dedicated review concluded the fibromyalgia-specific evidence remains inconclusive. That is an honest "not yet proven", not a hidden endorsement.
Fibromyalgia, the Nervous System and Pain
Fibromyalgia is understood less as a disease of the joints or muscles than as a disorder of how the nervous system processes pain. A central feature is central sensitisation — an amplification of pain signalling in the brain and spinal cord, so that ordinary stimuli are experienced as painful. Alongside this, many people with fibromyalgia show signs of autonomic dysfunction, including reduced parasympathetic (vagal) tone and altered heart rate variability.
Both of these intersect with the vagus nerve. The vagus contributes to the body's descending pain-modulation systems and is the main parasympathetic pathway, so in principle, enhancing vagal activity might dampen amplified pain signalling and help correct autonomic imbalance. This logic connects to our broader article on VNS for pain.
It is worth flagging one weakness in the rationale immediately, though. Part of the appeal rests on the idea that taVNS restores vagal tone — yet a 2026 systematic review found that transcutaneous VNS produced no consistent effect on heart rate variability across randomised trials (Souza et al., 2026). So even the autonomic half of the mechanism is not on firm ground.
The First Randomised Non-Invasive Trial: Kutlu 2020
The most relevant study for the ear-based devices people actually encounter is Kutlu et al. (2020), in BioMed Research International — the first randomised trial of auricular VNS in fibromyalgia. Sixty women with fibromyalgia (diagnosed by ACR 2010 criteria) were randomised to either 20 sessions of auricular VNS plus a home exercise programme, or the home exercise programme alone, over four weeks.
At first glance the result sounds positive: both groups improved significantly in pain, anxiety, depression, and quality of life. But the crucial comparison is between the groups, and here the trial fell short. The differences between VNS-plus-exercise and exercise-alone did not reach statistical significance on the main outcomes — pain (visual analogue scale, P = 0.084), fibromyalgia impact (FIQ, P = 0.378), depression, or anxiety. The stimulation group scored numerically better and reached significance on only a few quality-of-life subscales.
Two design features make this trial much weaker than it might appear:
It had no sham control and no blinding. The comparator was exercise alone, not exercise plus a fake stimulation — so participants in the VNS group knew they were receiving an extra, attention-rich treatment. Any apparent advantage is therefore confounded with placebo and attention effects. And in any case, the between-group differences on the primary pain and function measures were not statistically significant. This is best read as an inconclusive-to-negative result, not a demonstration that taVNS works.
It is, nonetheless, the first randomised look at the question, and it appropriately motivates the sham-controlled trials that have not yet been done.
An Earlier Invasive Pilot: Lange 2011
The other fibromyalgia-specific study is older and used a very different device. Lange et al. (2011), in Pain Medicine, reported a phase I/II proof-of-concept trial in which 14 patients received a surgically implanted vagus nerve stimulator. Twelve completed the initial three-month phase and eleven were followed to eleven months.
The signal was mixed but partly encouraging: at three months, five patients met the study's efficacy criteria and two no longer met the diagnostic criteria for fibromyalgia in terms of pain and tenderness, with more improving over longer follow-up. But the trade-offs were real — side effects resembled those seen with VNS in epilepsy and depression, plus dry mouth and fatigue, and two patients could not tolerate the stimulation.
The limitations are severe: this was a small (n=14), open-label trial with no sham control, using an invasive implanted device. It can suggest the approach is worth studying — but a positive signal in fourteen people who all knew they were being treated is a hypothesis, not a conclusion.
What the Broader Pain Evidence Suggests
Indirect support comes from the wider chronic-pain literature. Duff et al. (2024), in a systematic review and meta-analysis in Pain and Therapy, examined ear-based (auricular) VNS across chronic and acute pain conditions. For chronic pain, active stimulation produced a significant reduction in pain intensity compared with sham (effect size −1.95, P = 0.008). For acute and post-operative pain, the effect was not significant (−0.70, P = 0.15).
This is genuinely encouraging for the general idea that auricular VNS can help chronic pain — but two cautions apply. First, the analysis pooled various chronic-pain conditions and was not specific to fibromyalgia, so it cannot be read as direct evidence for it. Second, the chronic-pain literature is itself heterogeneous, with modest and variable effects. It raises the plausibility of benefit in fibromyalgia without demonstrating it.
Why the Evidence Remains Inconclusive
The most telling document is a review protocol. Cai et al. (2024), in Frontiers in Neurology, published a registered, PRISMA-compliant protocol for a systematic review and meta-analysis of VNS for fibromyalgia. The key point is what its existence implies: the authors set out to synthesise the evidence precisely because it "remains inconclusive", and the document is a plan for future analysis rather than a body of results.
Put together, the picture is clear. The only randomised non-invasive trial was unblinded and statistically negative between groups (Kutlu 2020); the only other primary study was a tiny open-label implant pilot (Lange 2011); and the broader supportive evidence is not fibromyalgia-specific (Duff 2024). There is, as of this writing, no published sham-controlled randomised trial of non-invasive taVNS for fibromyalgia with clearly positive results — which is the study that would actually move the needle.
Invasive Versus Non-Invasive
The two fibromyalgia studies sit on different devices, which is worth keeping straight. The implanted-device pilot (Lange 2011) and the non-invasive ear-device trial (Kutlu 2020) are not interchangeable, and neither provides strong evidence. In particular, there is no convincing, properly controlled evidence that the consumer-style ear devices relieve fibromyalgia. Marketing that implies otherwise is reaching well beyond the data.
Why Sham-Controlled Trials Matter So Much Here
Fibromyalgia is a condition in which the design flaws of the existing studies are especially consequential, and it is worth understanding why. Its core symptoms — pain, fatigue, and distress — are subjective, fluctuate over time, and are strongly responsive to placebo and to the attention that comes with being treated. These are precisely the conditions under which an unblinded study, or one without a sham control, will tend to overstate benefit.
That is exactly the weakness of the fibromyalgia evidence to date: the randomised trial added stimulation on top of exercise without a sham comparison (Kutlu et al., 2020), and the older study was open-label (Lange et al., 2011). In both, anyone receiving stimulation knew it, so expectation and attention cannot be separated from any genuine effect of the nerve stimulation itself. A properly blinded, sham-controlled trial — in which neither participants nor assessors know who is receiving real stimulation — is the only design that can answer the question, and it is the one piece of evidence the field is still missing.
Safety
Non-invasive taVNS is generally well tolerated, with mostly mild and transient effects — see our review of the safety profile of VNS. The older implanted-device trial showed that surgical VNS carries more substantial trade-offs, including intolerance in some patients. As always, safety is separate from efficacy, and a well-tolerated device can still lack proven benefit.
The Bottom Line
For fibromyalgia, the honest verdict is that the evidence is not yet there:
- The rationale (central sensitisation plus autonomic dysfunction) is plausible, though the vagal-tone premise is itself uncertain (Souza et al., 2026).
- The first randomised non-invasive trial was unblinded, had no sham control, and showed no significant benefit over exercise on its main outcomes (Kutlu et al., 2020).
- The only other primary study was a small, old, open-label implanted-device pilot (Lange et al., 2011).
- Broader chronic-pain evidence for auricular VNS is encouraging but not fibromyalgia-specific (Duff et al., 2024), and a dedicated review confirms the condition-specific evidence is inconclusive (Cai et al., 2024).
If you have fibromyalgia and are considering vagus nerve stimulation, the realistic position is that it is unproven for this condition — a reasonable subject for research, not an established treatment, and not something the current evidence on consumer devices supports. Discuss any option with your clinician, and treat strong marketing claims with scepticism. For the wider pain science, see our article on VNS for pain, and browse the studies in our Evidence Database.
---
References
Cai, Y. et al. (2024). Evaluating the efficacy and acceptability of vagus nerve stimulation for fibromyalgia: a PRISMA-compliant protocol for a systematic review and meta-analysis. Frontiers in Neurology, 15, 1367295.
Duff, I.T. et al. (2024). Clinical efficacy of auricular vagus nerve stimulation in the treatment of chronic and acute pain: a systematic review and meta-analysis. Pain and Therapy, 13(6), 1407–1427.
Kutlu, N. et al. (2020). The impact of auricular vagus nerve stimulation on pain and life quality in patients with fibromyalgia syndrome. BioMed Research International, 2020, 8656218.
Lange, G. et al. (2011). Safety and efficacy of vagus nerve stimulation in fibromyalgia: a phase I/II proof of concept trial. Pain Medicine, 12(9), 1406–1413.
Souza, R. et al. (2026). Neuromodulation of heart rate variability: a systematic review. Autonomic Neuroscience, 263, 103379.